Journal issues > Issue 5, September 2021 > Highlights in chronic myeloid leukaemia

Highlights in chronic myeloid leukaemia

SUMMARY

Chronic myeloid leukaemia (CML) received a lot of interest at EHA 2021. New ELN recommendations for CML management were presented, which highlighted the importance of risk stratification and cytogenetic analysis. The primary analysis of the phase II OPTIC study concluded that ponatinib showed dose-escalated efficacy in CML patients who were resistant to second-generation tyrosine kinase inhibitors (TKIs). Additionally, final analysis of the EURO-SKI trial revealed that TKI cessation might be appropriate in some CML patients. The Harmony Plus project shed light on the genetic heterogeneity of advanced CML. Finally, mutations in mitochondrial DNA were found to be associated with response to treatment with imatinib. The most important messages of these different presentations will be discussed in this article.

(BELG J HEMATOL 2021;12(5):225-7)

To read the full artice you have the following options:

* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Hematology in Belgium and Luxembourg with prescription authorisation)

Purchase this article for €3.03

** (for healthcare professionals with prescribing authorisation working outside the field of Hematology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Hematology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)

Top